New drug trial targets advanced lung cancer in First-Line treatment
NCT ID NCT07169552
Summary
This study is testing an experimental drug called HC010 for people with advanced non-small cell lung cancer who have not yet received treatment for their advanced disease. The trial will enroll 50 adults with specific cancer characteristics (PD-L1 positive) to see how well HC010 controls the cancer and how safe it is. Researchers will measure how many people's tumors shrink, how long the response lasts, and monitor for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, Shanghai Municipality, 200123, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.